Daily Cardiology Research Analysis
Three impactful cardiology studies stood out today. A multicenter Circulation analysis of 1,443 bicuspid aortic valve TAVR cases found no difference in death or stroke between balloon-expandable and self-expandable valves, but clear trade-offs in complications. An Annals of Internal Medicine network meta-analysis (65 studies, 40,022 participants) quantified systematic differences across blood pressure monitoring methods, challenging current hypertension thresholds. A Circulation mechanistic stud
Summary
Three impactful cardiology studies stood out today. A multicenter Circulation analysis of 1,443 bicuspid aortic valve TAVR cases found no difference in death or stroke between balloon-expandable and self-expandable valves, but clear trade-offs in complications. An Annals of Internal Medicine network meta-analysis (65 studies, 40,022 participants) quantified systematic differences across blood pressure monitoring methods, challenging current hypertension thresholds. A Circulation mechanistic study identified TRIM28–ERV–TLR7/9–NF-κB signaling as a driver of myocarditis and heart failure, revealing a novel therapeutic target.
Research Themes
- Transcatheter valve therapy comparative outcomes
- Hypertension measurement methodology and thresholds
- Heart failure pathophysiology via endogenous retroviruses
Selected Articles
1. Transcatheter Aortic Valve Replacement With Balloon- Versus Self-Expandable Bioprostheses for the Treatment of Bicuspid Aortic Valve Stenosis.
In 1,443 bicuspid TAVR patients, balloon-expandable and self-expandable valves had similar death/stroke rates up to 3 years, but distinct complication profiles. Balloon-expandable valves showed higher annulus rupture and transvalvular gradients, whereas self-expandable valves had more paravalvular regurgitation, additional valve implantation, and pacemaker implantation.
Impact: This large, multicenter comparative analysis provides clear trade-offs between valve platforms in bicuspid anatomy—a common but challenging subset—informing patient selection and procedural planning.
Clinical Implications: Device selection in bicuspid TAVR should balance risk of higher gradients and annulus rupture (balloon-expandable) against paravalvular regurgitation, need for second valve, and pacemaker (self-expandable). Pre-procedural planning and patient counseling should reflect these risks.
Key Findings
- Death or stroke did not differ at 30 days or 3 years between BE-THV and SE-THV (PSM HR ~1.0).
- BE-THV was associated with higher annulus rupture and higher mean transvalvular gradients.
- SE-THV had more paravalvular regurgitation, additional valve implantation, and higher PPM rates (30-day PPM HR 0.58 favoring BE-THV).
Methodological Strengths
- Large multicenter cohort with rigorous propensity matching and doubly robust adjustment
- Consistent results across multiple statistical approaches and early/new-generation devices with 3-year follow-up
Limitations
- Observational design without randomization leaves residual confounding possible
- Device selection bias and anatomical heterogeneity across centers
Future Directions: Randomized head-to-head trials in bicuspid anatomy and device design refinements to reduce PVL and gradients; development of pre-procedural risk models to personalize platform selection.
BACKGROUND: Differences between balloon- and self-expandable transcatheter heart valves (BE-THVs and SE-THVs, respectively) may influence the outcomes of transcatheter aortic valve replacement for bicuspid aortic valve (BAV) stenosis. METHODS: Consecutive patients undergoing transcatheter aortic valve replacement with BE-THV or SE-THV for computed tomography-diagnosed bicuspid aortic valve stenosis at 29 centers were included. The primary outcome was death or stroke. After propensity score matching in 10 data sets generated by multiple imputation, outcomes from transcatheter aortic valve replacement to 3-year follow-up were computed by multivariable binomial logistic mixed-effects models, multivariable linear mixed-effects models, or multivariable frailty models accounting for center-related influences and residual confounding effects (doubly robust adjustment). The results were replicated by inverse probability of treatment weighting and multivariable adjustment. RESULTS: A total of 1443 consecutive patients with bicuspid aortic valve stenosis undergoing BE-THV (n=860) or SE-THV (n=583) implantation were included. In-hospital and 30-day death or stroke did not significantly differ between BE-THV and SE-THV groups (5.1% versus 6.1%; hazard ratio after propensity score matching, 1.02 [95% CI, 0.51-2.02]). BE-THV implantation was associated with higher annulus rupture and mean transvalvular gradient compared with SE-THV implantation. In contrast, SE-THV implantation was associated with higher additional valve implantation and paravalvular regurgitation compared with BE-THV implantation. The results were consistent across the statistical methods used and between early- and new-generation THVs. At 30 days, pacemaker implantation was lower in the BE-THV group compared with the SE-THV group (11.9% versus 18.6%; hazard ratio after propensity score matching, 0.58 [95% CI, 0.36-0.93]). This result did not depend on the statistical method used. At 3 years, consistent with the 1- and 2-year analyses, death or stroke was not significantly different between the BE-THV and SE-THV groups (23.7% versus 26.2%; hazard ratio after propensity score matching, 0.99 [95% CI, 0.65-1.51]). Death or stroke across major clinical, anatomical, functional, and procedural conditions was consistent with the main analysis. After inverse probability of treatment weighting and multivariable adjustment, these conclusions remained unchanged. CONCLUSIONS: In patients undergoing transcatheter aortic valve replacement for bicuspid aortic valve stenosis, death or stroke does not significantly differ between those receiving a BE-THV and those receiving an SE-THV over a follow-up of 3 years. BE-THV is associated with higher transvalvular mean gradient and more frequent annulus rupture, whereas SE-THV is associated with more frequent moderate to severe aortic regurgitation, additional THV implantation, and permanent pacemaker implantation.
2. Agreement Between Different Types of Blood Pressure Monitoring : A Systematic Review and Network Meta-analysis.
Across 65 studies (40,022 participants), systolic BP differed systematically by monitoring method versus research-grade office BP: automated office, home, and daytime ABPM were ~4–5 mm Hg lower; nighttime ABPM was ~18 mm Hg lower; 24-hour ABPM ~9 mm Hg lower; and convenient office BP ~3 mm Hg higher. Discrepancies increased at higher BP levels.
Impact: By quantifying method-specific offsets and their dependence on BP level, this analysis challenges one-size-fits-all thresholds and supports method-calibrated targets in guidelines.
Clinical Implications: Hypertension diagnosis and treatment thresholds should consider the specific BP method used (e.g., lower nighttime ABPM). Clinicians should avoid direct substitution of values across methods and consider method-adjusted targets, especially in patients with higher BP.
Key Findings
- Convenient office systolic BP averaged +2.69 mm Hg vs research office; automated office, home, and daytime ABPM were ~4–5 mm Hg lower.
- Nighttime ABPM showed the largest negative offset (−18.14 mm Hg); 24-hour ABPM was −8.63 mm Hg.
- Method discrepancies increased at higher reference BP levels per meta-regression.
Methodological Strengths
- Pre-registered (PROSPERO) network meta-analysis with meta-regression across BP strata
- Large evidence base (65 studies, 40,022 participants) and formal risk-of-bias assessments
Limitations
- Heterogeneity from mixed study designs and device protocols
- Office research BP as reference may itself vary across studies; limited IPD analyses
Future Directions: Develop method-specific diagnostic/treatment thresholds and standardized protocols; IPD harmonization to refine calibration equations across methods and BP ranges.
BACKGROUND: Accurate blood pressure measurement (BPM) is essential for managing hypertension, but previous studies have not systematically compared different monitoring methods across varying BP levels. To address this gap, a comprehensive analysis using network meta-analysis (NMA) and meta-regression was done to evaluate their agreement and clinical implications. PURPOSE: To compare BP values obtained using different BPM methods using office BPM (OBPM) as the reference. DATA SOURCES: Studies published in MEDLINE and Scopus up to October 2024. STUDY SELECTION: Studies aimed to compare the values between BPM methods in participants older than 18 years. DATA EXTRACTION: Risk of bias was assessed on the basis of the internal validity of the study overall and the quality of the BPM methods. The mean differences between BPMs were calculated using NMA and meta-regression. DATA SYNTHESIS: Sixty-five studies encompassing 40 022 participants were analyzed. Compared with research office systolic BPM, the pooled mean differences from corresponding systolic BPs were 2.69 mm Hg (95% CI, -0.13 to 5.51 mm Hg) higher for convenient OBPM, 4.57 mm Hg (CI, 2.54 to 6.60 mm Hg) lower for automated OBPM, 4.59 mm Hg (CI, 2.83 to 6.34 mm Hg) lower for home BPM, 4.22 mm Hg (CI, 2.62 to 5.82 mm Hg) lower for daytime ambulatory BPM (ABPM), 18.14 mm Hg (CI, 16.21 to 20.06 mm Hg) lower for nighttime ABPM, and 8.63 mm Hg (CI, 6.97 to 10.28 mm Hg) lower for 24-hour ABPM. Differences varied by reference research OBPM levels: Higher reference BP levels are associated with larger differences between research office and other BPM methods. LIMITATION: Heterogeneity due to the inclusion of studies with different research designs. CONCLUSION: Our analysis found differences among BPM methods that varied from the recommendations of current hypertension guidelines. Furthermore, discrepancies were more pronounced at elevated BP levels. PRIMARY FUNDING SOURCE: Ministry of Health and Welfare, Taiwan. (PROSPERO: CRD42021246448).
3. An Aberrant Resurgence of Endogenous Retroviruses Prompts Myocarditis and Heart Failure.
Across human and murine models, class I endogenous retroviruses are reactivated in heart failure. Cardiomyocyte TRIM28 depletion permits ERV resurgence, activating TLR7/9–NF-κB signaling to drive myocarditis and heart failure; conversely, blocking ERV inception or pathway signaling confers cardiac protection.
Impact: Identifies a previously unrecognized molecular driver of myocarditis and heart failure, linking ERV resurgence to innate immune activation—a potentially druggable axis.
Clinical Implications: While preclinical, these data justify translational efforts to target TRIM28–ERV–TLR7/9–NF-κB signaling (e.g., TLR7/9 inhibition or ERV suppression) in myocarditis and select heart failure phenotypes.
Key Findings
- Class I ERVs are prominently reactivated in multiple cross-species heart failure models.
- Cardiomyocyte TRIM28 depletion diminishes epigenetic repression, enabling ERV resurgence and activating TLR7/9–NF-κB signaling.
- Interventions blocking ERV inception or downstream innate immune signaling mitigate myocarditis and heart failure.
Methodological Strengths
- Cross-species validation with human and murine models and comprehensive transcriptomic profiling
- Genetic manipulation of TRIM28 and pathway interrogation providing mechanistic causality
Limitations
- Preclinical study; translational applicability requires validation in human tissues and trials
- Potential off-target effects of pathway modulation not fully characterized
Future Directions: Develop specific inhibitors/modulators of TRIM28–ERV–TLR7/9–NF-κB axis; define biomarkers of ERV activation in human HF; stratify myocarditis/HF phenotypes responsive to pathway blockade.
BACKGROUND: Endogenous retroviruses (ERVs) occupy >8% of the human genome. Aberrant resurgence of ERVs has been implicated recently in several critical pathologies. However, the possible incidence and role of ERV resurgence in heart failure (HF), a leading cause of global morbidity and mortality, remain unexplored. METHODS: We established a total RNA sequencing analyzing pipeline to assess the ERV occurrence in human and murine HF models. We generated 2 myocardium-specific mouse lines by crossing RESULTS: ERVs, particularly class I ERVs, were prominently activated in multiple cross-species models of HF. Depletion of TRIM28, an epigenetic repressor, attenuated the epigenetic surveillance of trimethylation at lysine 9 of histone H3 and CONCLUSIONS: ERV resurgence is a specific molecular trait of HF, driven by TRIM28 depletion in cardiomyocytes. ERV resurgence activates the innate immune TLR7/9-NF-κB pathway and induces myocarditis and HF. Inception of ERVs and the ERV-mediated immune pathway confers cardiac protection. These results identify TRIM28-ERV-TLR7/9-NF-κB as a target for therapeutic management of myocarditis and HF.